These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of malignant features in oligodendroglial tumors. Saito A, Nakazato Y. Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700 [Abstract] [Full Text] [Related]
4. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases. Jentoft M, Giannini C, Rossi S, Mota R, Jenkins RB, Rodriguez FJ. Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114 [Abstract] [Full Text] [Related]
5. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas. Majumdar K, Radotra BD, Vasishta RK, Pathak A. Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929 [Abstract] [Full Text] [Related]
6. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. Nayak A, Ralte AM, Sharma MC, Singh VP, Mahapatra AK, Mehta VS, Sarkar C. Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478 [Abstract] [Full Text] [Related]
7. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Ozen O, Demirhan B, Altinörs N. Clin Neuropathol; 2005 Jun; 24(5):219-24. PubMed ID: 16167545 [Abstract] [Full Text] [Related]
8. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179 [Abstract] [Full Text] [Related]
12. Molecular control of the cell cycle in cancer: biological and clinical aspects. Møller MB. Dan Med Bull; 2003 May 01; 50(2):118-38. PubMed ID: 12812137 [Abstract] [Full Text] [Related]